Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
2025 Dec;18(12):611-619
The pipeline continues to expand: Novo Nordisk filed an NDA for CagriSema (semaglutide + cagrilintide) in December 2025, which achieved 22.7% weight loss in the REDEFINE 1 trial, and Eli Lilly reported Phase 3 results for retatrutide , a triple GIP/GLP-1/glucagon agonist that delivered 28.7% weight loss
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study
Residual solvent panel and sterility testing are the next tier
Heart J
US$ 27.36
US$ 25.30
US$ 22.86
US$ 29.73
